← All trials
NCT02341456
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 16, 2015
- Primary completion
- Dec 14, 2016
- Completion date
- Jun 27, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 19
- Arms / groups
- 3 / —
- Source
- AACT · pre-existing
Sponsors
- AstraZenecaLead sponsor
- Sungkyunkwan UniversityOverall official - principal investigator
- NCC HospitalOverall official - principal investigator
- University of New South WalesOverall official - principal investigator
- University of UlsanOverall official - principal investigator
- Seoul National UniversityOverall official - principal investigator
- Nucleus Network LtdOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.